| Literature DB >> 35884740 |
Helen Baldwin1,2, Lion Loebel-Davidsohn3, Dominic Oliver1, Gonzalo Salazar de Pablo1,4,5,6, Daniel Stahl7, Heleen Riper8,9,10, Paolo Fusar-Poli1,2,11,12.
Abstract
BACKGROUND: Despite significant research progress surrounding precision medicine in psychiatry, there has been little tangible impact upon real-world clinical care.Entities:
Keywords: barriers; facilitators; precision medicine; psychiatry; real-world implementation; systematic review
Year: 2022 PMID: 35884740 PMCID: PMC9313345 DOI: 10.3390/brainsci12070934
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Inclusion and exclusion criteria.
| Inclusion Criteria | Exclusion Criteria | |
|---|---|---|
|
Consultation with key stakeholders |
Health and social care professionals Service users and family members and/or caregivers Policymakers Research scientists Local community members | NA |
|
Precision psychiatry approach |
Diagnostic, predictive or prognostic models employing a precision (or stratified) approach Specific to the field of psychiatry (i.e., any DSM/ICD diagnosis) |
Precision models relating to traumatic brain injury, neurological disorders or dementias |
|
Predictors |
Clinical Sociodemographic Service use Behavioural Biomarkers (neuroimaging, genomic, pharmacogenomic, metabolomic, cognitive) Any combination of the above | NA |
|
(IV) Study design |
Primary research studies which consider actual or proposed implementation Qualitative, quantitative or mixed methods |
▪ Secondary research (systematic and non-systematic reviews, and meta-analyses) a |
|
(V) Assessment of barriers/ facilitators |
Systematic assessment of barriers and/or facilitators to precision (or stratified) psychiatry |
Assessment of barriers and/or facilitators only raised in the discussion section |
|
Publication type |
Conference abstracts b Full journal articles |
Protocols Editorials, letters and commentaries Expert opinion papers c |
|
Level and quality of evidence |
Any level or quality of evidence | NA |
|
Language |
Any language | NA |
|
(IX) Publication date |
Published from database inception to 25 October 2020 | NA |
a Reviews were screened for relevant research via the hand-searching of bibliographies. b Conference abstracts were only included if they fit all other criteria, including the reporting of primary research data. c Expert opinion papers were flagged for inclusion should the final literature base be too narrow to facilitate sufficient discussion (<5 studies). DSM = Diagnostic Statistical Manual (any version); ICD = International Classification of Diseases (any version).
Figure 1Preferred reporting items for systematic reviews and meta-analyses (PRISMA) diagram detailing the full study selection process.
Figure 2The stakeholder groups investigated across the included literature and the proportion (%) of studies consulting each group.
Figure 3The fields of psychiatry investigated across the included literature and the proportion (%) of studies investigating each field.
Figure 4The precision psychiatry approaches adopted across the included literature and the proportion (%) of studies investigating each approach.
Characteristics of the included studies.
| First Author, Date | Location | Research Method | Field of Psychiatry | Type of Precision Model | Sample | Level of Evidence | Summary of Barriers | Summary of Facilitators |
|---|---|---|---|---|---|---|---|---|
| Bellón, 2014 [ | Spain | Focus groups | Depression | Individualised risk prediction algorithm | 52 service-users | 1 | Resistance to knowledge of risk scores; Negative attitudes towards psychiatry | Adequate skills and competence training; Availability of effective interventions and counselling |
| Brown, 2020 [ | United States | Survey | Suicidal behaviours | Individualised risk prediction algorithm | 139 health care professionals (psychologists, social workers, psychiatrists, nurses and other allied health professionals) | 1 | Poor accuracy and utility of the model; Poor transparency and complexity of the model | N/A |
| Chan, 2017 [ | Singapore | Survey | General psychiatry | Pharmaco-genomics | 167 doctors and 27 pharmacists ( | 1 | Poor perceived competence in precision medicine; Negative staff perceptions of precision medicine; Cost and time investments; Lack of clear guidelines; Potential psychological harm; Potential economic and occupational harm | Availability of associated infrastructure |
| Doraiswamy, 2020 [ | North America, South America, Europe and Asia-Pacific | Survey | General psychiatry | General AI/ML applications | 791 psychiatrists | 1 | Poor perceived relative advantage of the model; Negative staff perceptions of precision medicine | N/A |
| Dunbar, 2012 [ | New Zealand | Surveys and interviews | General psychiatry | Pharmaco-genomics | 33 senior medical officers and registrars | 1 | Lack of clinical resources; Poor perceived competence in precision medicine; Poor perceived relative advantage of the model; Cost and time investments; Potential psychological harm | N/A |
| Erickson, 2013 [ | United States | Survey | Mood disorders | Genetic testing | 147 service users, caregivers and community members, and mental health professionals | 1 | Negative staff perceptions of precision medicine; Scepticism in genetics | Availability of associated infrastructure |
| Evanoff, 2016 [ | United States | Stakeholder meetings | General psychiatry | Genomics | Health care professionals, research scientists, and community members ( | 1 | Poor accuracy and utility of the model | Engagement and community outreach |
| Finn, 2005 [ | United States | Survey | General psychiatry | Genetic testing | 844 psychiatrists or psychiatrists-in-training | 1 | Potential stigmatisation; Potential economic and occupational harm; Lack of clinical resources; Poor perceived competence in precision medicine | N/A |
| Goodspeed, 2019 [ | United States | Focus groups and prototype development | General psychiatry | Pharmaco-genomics integrated into a clinical decision support system | 16 mental health clinicians | 1 | Poor perceived relative advantage of the model; Poor previous experience; Cost and time investments | Integration into current workflow |
| Henshall, 2017 [ | United Kingdom | Focus groups and prototype feedback | General psychiatry | Clinical decision support system | 12 consultant psychiatrists, 11 primary care practitioners and 8 patients/carers ( | 1 | Poor perceived relative advantage of the model; Potential psychological harm; Poor transparency and complexity of the model; Cost and time investments; Poor accuracy and utility of the model | Collaborative usage; Trusting service user/clinician relationship; Multi-modal models; Simplicity and usability of the model |
| Hoop, 2008 [ | United States | Survey | General psychiatry | Genetic testing | 45 psychiatrists | 1 | Lack of clinical resources; Poor perceived competence in precision medicine | Availability of associated infrastructure |
| Hoop, 2010 [ | United States | Survey | General psychiatry | Pharmaco-genomics | 75 psychiatry attending physicians and residents | 1 | Potential psychological harm; Potential economic and occupational harm; Poor accuracy and utility of the model; Cost and time investments; Lack of clinical resources; Negative staff perceptions of precision medicine | Confidentiality of personal data; Adequate skills and competence training; Availability of effective interventions and counselling |
| Illes, 2008 [ | United States | Survey | Major depression | Functional brain imaging | 52 psychiatrists or psychologists, and 72 inpatient and outpatient service users ( | 1 | Cost and time investments; Potential psychological harm; Potential economic and occupational harm | N/A |
| Jenkins, 2016 [ | United Kingdom | Face-to-face and telephone interviews | General psychiatry | Genetic testing | 9 psychiatric staff nurses and consultant psychiatrists | 1 | Poor transparency and complexity of the model; Poor accuracy and utility of the model; Poor perceived competence in precision medicine; Weak demand and engagement; Potential psychological harm; Potential stigmatisation | Availability of associated infrastructure; Adequate skills and competence training |
| Laegsgaard, 2008 [ | Denmark | Questionnaire | General psychiatry | Genetic testing | 681 patients and relatives | 1 | Potential misuse of personal data; Scepticism in genetics | Confidentiality of personal data |
| Lucero, 2020 [ | United States | Survey | General psychiatry | Pharmaco-genomics | 830 psychiatrists | 1 | N/A | Adequate skills and competence training |
| Mathews, 2018 [ | United States | Feasibility study | Child psychiatry | Pharmaco-genomics | Parents and associated clinicians of 73 young service users | 2 | Cost and time investments; Fear of invasive procedures | Adequate skills and competence training |
| Moreno-Peral, 2018 [ | Spain | Face-to-face semi-structured interviews | Major depression | Individualised risk prediction algorithm | 67 family physicians | 2 | Cost and time investments; Poor transparency and complexity of the model; Lack of motivation to address mental health in primary care; Potential psychological harm | Simplicity and usability of the model; Stratification over precision; Integration into current workflow; Adequate skills and competence training; Effective time management and organisation |
| Oliver, 2020 [ | United Kingdom | Feasibility study | Clinical high-risk for psychosis | Transdiagnostic risk calculator | Clinicians of 3722 patients screened and independent consultation with an unspecified number of service users and clinicians | 2 | N/A | Routinely collected predictors; Outreach to local clinicians and clinical prompts |
| Reger, 2019 [ | United States | Case example | Suicidal behaviours | Clinical prediction model | A clinical implementation team of professionals | 2 | Lack of effective interventions; Lack of clinical resources | Outreach to local clinicians and clinical prompts; Compliance with law and regulatory pathways |
| Salm, 2014 [ | United States | Survey | General psychiatry | Genetic testing | 372 psychiatrists and 163 neurologists ( | 1 | Potential misuse of personal data; Poor perceived competence in precision medicine; Potential psychological harm; Potential economic and occupational harm | Adequate skills and competence training |
| Smith, 1996 [ | United States | Survey | Bipolar disorder | Genetic testing | 48 members of a bipolar disorder support group, 35 medical students and 30 psychiatry residents ( | 1 | Lack of effective interventions | N/A |
| Trippitelli, 1998 [ | United States | Questionnaire | Bipolar disorder | Genetic testing | 90 service users and their spouses | 1 | Potential misuse of personal data; Potential stigmatisation; Potential economic and occupational harm | N/A |
| Wachtler, 2018 [ | Australia | Focus group, prototype development and semi-structured interviews | Depression | Clinical prediction model | 17 members and of the community and 7 service users ( | Poor transparency and complexity of the model;Ethics of risk communication; Potential psychological harm; Poor accuracy and utility of the model | Adaptability of the model | |
| Walden, 2015 [ | Canada | Survey | General psychiatry | Pharmaco-genomics | 168 physicians who had ordered pharmaco-genomic tests for psychotropic medication | 1 | Negative staff perceptions of precision medicine | N/A |
| Wilde, 2010 [ | Australia | Focus groups | Major depression | Genetic testing | 36 members of the public (14 with disclosure of family history of mental illness) | 1 | Poor perceived relative advantage of the model; Poor accuracy and utility of the model; Potential misuse of personal data; Lack of effective interventions; Potential psychological harm; Potential stigmatisation; Potential economic and occupational harm | Integration into workflow |
| Williams, 2016 [ | United States | Semi-structured interviews | Alcohol use disorders | Genetic testing | 24 primary care providers | 1 | Cost and time investments; Poor accuracy and utility of the model; Lack of clinical resources; Negative staff perceptions of precision medicine; Potential psychological harm | Patient engagement |
| Zhou, 2014 [ | Australia | Survey | Schizophrenia, bipolar disorder and major depression. | Genetic testing | 104 psychiatrists, 36 genetic counsellors, and 17 medical geneticists ( | 1 | Poor perceived competence in precision medicine; Potential economic and occupational harm | N/A |
Records marked with * represent a conference abstract; all other records are full journal publications. Records marked with represent those employing actual implementation methods as opposed to hypothetical or simulated implementation. Quality ratings: 3 = Randomized Controlled Trials, 2 = Pilot and feasibility studies, 1 = All other primary research involving stakeholder consultation. AI = Artificial Intelligence; CDS = Clinical Decision Support; ML = Machine Learning.
Figure 5A high-level visual summary of the identified barriers and facilitators which may impact upon the real-world implementation of precision psychiatry approaches, structured according to the Consolidated Framework for Implementation Research (CFIR).
Figure 6Proportion (%) of the included studies reporting each barrier.
Figure 7Proportion (%) of the included studies reporting each facilitator.